Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK102 in Homozygous Familial Hypercholesterolemia
NCT03933293Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- May 2019
- Primary completion
- Mar 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ebronucimab in homozygous familial hypercholesterolemia (HoFH), sponsored by Akeso, Inc.. Started May 2019; status: completed.
02
Drugs
ebronucimab
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NCT03933293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03933293.